UK islet autoantibody registry for early Type 1 diabetes
Official title: UK Islet Autoantibody Registry
Run by University of Oxford · NCT07125365 · Data updated 2026-11-12
This UK registry collects health and antibody information from people with one or more islet autoantibodies to track who develops Type 1 diabetes and to connect them with monitoring or prevention options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Months to 70 Years |
| Sex | All |
| Enrollment | 350 (estimated) |
| Sponsor | University of Oxford Academic / other |
| Locations | 1 site (Oxford, Oxfordshire) |
| Status | Recruiting |
| Started | July 11, 2025 |
| Main results expected | May 31, 2027 |
| Study ends | May 31, 2027 |
| Registry record updated | August 15, 2025 |
| Trial ID | NCT07125365 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are UK residents aged 6 months to 70 years with at least one laboratory-confirmed islet autoantibody and who are not currently insulin-dependent.
✕Probably not a fit
People who already require ongoing subcutaneous insulin (established clinical Type 1 diabetes), those outside the age range, or those living outside the UK are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational registry that enrolls people aged 6 months to 70 years living in the UK who have at least one confirmed islet autoantibody (insulin, GAD, IA-2, or ZnT8). Participants' clinical data and antibody results are recorded and followed over time to document progression between preclinical stages and clinical Type 1 diabetes. The registry links with existing cohort initiatives (such as ADDRESS-2) and includes opportunities for qualitative interviews about living with a positive antibody result. No investigational treatments are given as part of the registry, but the collected data support earlier detection of progression and help identify candidates for future prevention trials.
Why it matters
Potential benefit: If successful, the registry could enable earlier identification and monitoring of people at high risk of Type 1 diabetes, reduce emergency presentations like diabetic ketoacidosis, and speed recruitment into prevention studies.
How similar studies have gone: Large longitudinal cohorts have already shown that having two or more islet autoantibodies strongly predicts progression to clinical Type 1 diabetes (over 80% within 15 years), so this registry builds on established predictive findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female, aged 6 months - 70 years * IAb positive (≥ 1) to any of the following: insulin/GAD/IA2/ZnT8, confirmed in a reference laboratory. * Participant is willing and able to give informed consent for participation in the study (≥ 16 years old), or for \< 16 years, parental/guardian consent (plus assent, where appropriate) * Living in the UK * For ADDRESS-2 participants only: have taken part in a blood draw as part of ADDRESS-2 * For the qualitative interviews: Have been living with (or is a parent/guardian of a child who has been living with) a positive IAb result for ≥ 6 months. Exclusion Criteria: * Ongoing subcutaneous insulin requirement
Where it's running
-
University of Oxford
Oxford, Oxfordshire, United Kingdom Recruiting
Study contacts
- Principal investigator: Rachel Besser — University of Oxford
- Study coordinator: UKIAb Registry Manager
- Email: ukiab@ndm.ox.ac.uk
- Phone: +44(0)7765 932065
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
INNODIA Family & Friends Early-Stage Type 1 Diabetes Detection
This program tests blood autoantibody screening to find people aged 1 to 45 who, because they have a relative or close friend with Type 1 diabetes, may be at higher risk of developing T1D.
-
Benefits of Retained Insulin for Good Health in Diabetes
This study tests whether preserving or restoring a person’s own insulin production can improve quality of life and blood sugar control for people who need insulin to manage diabetes.
-
Intermittent CGM Use in high-risk children and teens with Type 1 Diabetes in the Dominican Republic
This study tests whether using the Dexcom G7 intermittently, along with pediatric care and support, can improve glucose control in 10–19 year-olds with high-risk Type 1 Diabetes in the Dominican Republic.
-
AI-assisted remote insulin pump optimization for people with type 1 diabetes
This study tests an AI-powered tool that suggests insulin pump settings for people with type 1 diabetes, with doctor-approved recommendations delivered to a mobile app.
-
High-Intensity Interval Training vs. Continuous Endurance Training in Prediabetes
This study tests whether short bursts of intense exercise or steady, longer workouts can improve blood sugar control and fitness in people with prediabetes.
-
AMX0035 in adults with Type 1 Diabetes
This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.